Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells $23,483.18 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 5,686 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $4.13, for a total value of $23,483.18. Following the transaction, the insider owned 559,359 shares of the company’s stock, valued at approximately $2,310,152.67. This represents a 1.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The shares were sold at an average price of $4.04, for a total value of $15,352.00.
• On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The stock was sold at an average price of $4.32, for a total value of $66,026.88.
• On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47.
• On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The shares were sold at an average price of $5.08, for a total transaction of $21,026.12.
• On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total transaction of $32,218.36.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total transaction of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total transaction of $67,377.80.
• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total transaction of $61,200.95.
• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The stock was sold at an average price of $4.80, for a total value of $59,673.60.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The stock was sold at an average price of $5.13, for a total value of $40,644.99.

Clene Stock Performance

Shares of NASDAQ CLNN opened at $3.99 on Thursday. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The firm has a market cap of $43.29 million, a P/E ratio of -1.18 and a beta of 0.81. The stock has a fifty day moving average price of $6.02 and a two-hundred day moving average price of $6.55.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. On average, research analysts predict that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on CLNN shares. Benchmark reissued a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. UBS Group restated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Clene in a report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Scoggin Management LP raised its position in Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares during the period. Lunt Capital Management Inc. boosted its position in Clene by 2.5% during the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after acquiring an additional 1,250 shares during the period. Jones Financial Companies Lllp purchased a new position in Clene during the 3rd quarter valued at about $29,000. Finally, Jane Street Group LLC acquired a new position in shares of Clene in the 2nd quarter valued at about $47,000. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).